CINECA IRIS Institutional Research Information System

LA MOTTA, CONCETTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.848
AS - Asia 8.112
EU - Europa 8.006
SA - Sud America 1.134
Continente sconosciuto - Info sul continente non disponibili 557
AF - Africa 360
OC - Oceania 38
Totale 37.055
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.299
IT - Italia 3.175
SG - Singapore 2.480
CN - Cina 2.217
SE - Svezia 1.466
HK - Hong Kong 1.187
BR - Brasile 910
VN - Vietnam 739
DE - Germania 733
BG - Bulgaria 493
TR - Turchia 452
GB - Regno Unito 406
CA - Canada 401
FR - Francia 363
FI - Finlandia 283
AT - Austria 271
RU - Federazione Russa 251
IN - India 244
JP - Giappone 186
UA - Ucraina 163
KR - Corea 108
CI - Costa d'Avorio 99
CH - Svizzera 82
BD - Bangladesh 76
NL - Olanda 73
NG - Nigeria 72
MX - Messico 65
PK - Pakistan 65
PL - Polonia 51
AR - Argentina 50
IQ - Iraq 50
ID - Indonesia 46
SA - Arabia Saudita 45
CO - Colombia 41
BE - Belgio 40
VE - Venezuela 40
ZA - Sudafrica 40
ES - Italia 36
AU - Australia 32
EC - Ecuador 31
MA - Marocco 31
UZ - Uzbekistan 29
JO - Giordania 22
SN - Senegal 22
IE - Irlanda 21
EG - Egitto 20
MY - Malesia 19
CR - Costa Rica 18
KE - Kenya 18
PE - Perù 18
CZ - Repubblica Ceca 16
JM - Giamaica 16
CL - Cile 15
DZ - Algeria 15
AZ - Azerbaigian 14
GR - Grecia 14
PH - Filippine 14
UY - Uruguay 13
IR - Iran 12
KZ - Kazakistan 11
LT - Lituania 11
PY - Paraguay 11
AE - Emirati Arabi Uniti 10
DK - Danimarca 9
LB - Libano 9
TH - Thailandia 9
TN - Tunisia 9
TW - Taiwan 9
AL - Albania 8
HN - Honduras 8
IL - Israele 8
NO - Norvegia 7
PS - Palestinian Territory 7
RS - Serbia 7
TT - Trinidad e Tobago 7
GT - Guatemala 6
NP - Nepal 6
OM - Oman 6
SY - Repubblica araba siriana 6
ET - Etiopia 5
GE - Georgia 5
NI - Nicaragua 5
NZ - Nuova Zelanda 5
PA - Panama 5
PT - Portogallo 5
AO - Angola 4
KH - Cambogia 4
MK - Macedonia 4
SV - El Salvador 4
BJ - Benin 3
BO - Bolivia 3
CG - Congo 3
DO - Repubblica Dominicana 3
LY - Libia 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
BN - Brunei Darussalam 2
CY - Cipro 2
GA - Gabon 2
Totale 36.447
Salva come PNG Salva come JPEG
Città #
Ashburn 1.986
Woodbridge 1.634
Singapore 1.434
Ann Arbor 1.361
Houston 1.231
Hong Kong 1.165
San Jose 1.136
Fairfield 1.066
Chandler 939
Serra 883
Santa Clara 858
Dallas 844
Milan 610
Beijing 500
Sofia 489
Seattle 457
Shanghai 449
Wilmington 411
New York 378
Cambridge 358
Council Bluffs 350
Izmir 308
Los Angeles 301
Ottawa 267
Boardman 262
Princeton 230
Jacksonville 214
Vienna 199
Lawrence 192
Lauterbourg 178
Dong Ket 168
Hefei 168
Nanjing 163
Ho Chi Minh City 158
Medford 158
London 156
Tokyo 153
Rome 144
Frankfurt am Main 127
Des Moines 116
Hanoi 104
Helsinki 103
Seoul 103
Istanbul 102
Abidjan 99
Buffalo 92
Dearborn 89
Munich 88
Rho 85
Chicago 84
São Paulo 82
Pisa 79
Florence 78
Redondo Beach 73
Lagos 69
Columbus 64
Bremen 62
Redwood City 56
The Dalles 55
Lucca 52
San Diego 52
Boulder 51
Bern 49
Nanchang 48
Düsseldorf 44
Toronto 42
Brussels 40
Shenyang 39
Phoenix 38
Warsaw 38
Fuzhou 37
Jüchen 36
Kunming 36
San Francisco 36
Pune 35
Hebei 32
Washington 32
Belo Horizonte 31
Falls Church 31
Marseille 31
Ogden 31
Rio de Janeiro 31
Orem 30
Nuremberg 29
Figino 28
Baghdad 26
Tashkent 26
Zurich 26
Brooklyn 25
Chennai 25
Montreal 25
Guangzhou 23
Changsha 22
Dakar 22
Denver 21
Haiphong 21
New Delhi 21
Turku 21
Amman 20
Atlanta 20
Totale 25.091
Salva come PNG Salva come JPEG
Nome #
Derivati isoindolici come attivatori di AMPK 547
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 426
A new class of tyrosine kinase inhibitors, “pyrazolo[3,4-d]pyrimidinic”compounds, has antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer 381
Preparation of isoindoline derivatives for use as AMPK activators 352
Soyasaponins from Zolfino bean as aldose reductase differential inhibitors 291
Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors, 283
Benzofuroxane Derivatives as Multi Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies 282
Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas 277
Derivati benzofuranici come attivatori di AMPK 271
N-(aroyl)-N-(arylmethyloxy)-α-alanines: selective inhibitors of aldose reductase 268
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 262
Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors 261
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 257
Deepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamides 250
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 246
[1,2,4]Triazino[4,3-a]benzimidazole Acetic Acid Derivatives: a New Class of Selective Aldose Reductase Inhibitors 244
Functional Studies in the Year of Pulses: the case of Zolfino landraces (Phaesolus vulgaris L.) 243
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 241
Sulfonamides incorporating heteropolycyclic scaffolds show potent inhibitory action against carbonic anhydrase isoforms I, II, IX and XII 235
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 234
[1,2,4]Triazino[4,3-a]benzimidazole Acetic Acid Derivatives: A New Class of Selective Aldose Reductase Inhibitors 229
Synthesis and investigation of polyhydroxylated pyrrolidine derivatives as novel chemotypes showing dual activity as glucosidase and aldose reductase inhibitors 229
How Reliable Are Current Docking Approaches for Structure-based Drug Design? Lessons from Aldose Reductase 228
Hemp (Cannabis sativa L.) flour: an active ingredient for the formulation of nutritious, flavorful and affordable foods. 228
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors 222
Complexing the Marine Sesquiterpene Euplotin C by Means of Cyclodextrin-Based Nanosponges: A Preliminary Investigation 220
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of non-camptothecin Topoisomerase I (Top1) inhibitors 220
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 219
3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: Tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands 219
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 218
Identification of Anxiolytic/Nonsedative Agents among Indol-3-ylglyoxylamides Acting as Functionally Selective Agonists at the γ-Aminobutyric Acid-A (GABAA) α2 Benzodiazepine Receptor 216
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: A New Class of Selective A1 Adenosine Receptor Antagonists 216
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: A Novel Template for the Design of Highly Selective A(2B) Adenosine Receptor Antagonists. 214
Evidence for a Novel Binding Site Conformer of Aldose Reductase in Ligand-Bound State 213
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 212
A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis 209
“Synthesis and antiproliferative evaluation of new substituted Benzothiopyrano[4,3-c] condensed ring systems” 208
Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands 208
New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors 208
Studies in search for selective ligands for GABAA/BzR receptor subtypes: synthesis and biological evaluation of 4'-modified N-(benzyl)indol-3-ylglyoxylamides 207
Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects 206
Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity 206
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A(2B) adenosine receptor antagonists 205
Novel Pyrazolo[3,4-d]pyrimidine Derivatives as ATP-competitive Inhibitors of the Epidermal Growth Factor Receptor Protein Tyrosine Kinase 203
2-(Benzimidazol-2-yl)quinoxalines: A Novel Class of selective Antagonists at Human A1 and A3 Adenosine Receptors Designed by 3D Database Searching 202
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 202
Refinement of Structure-activity Relationships of the Triazinobenzimidazole A1AR Antagonists 201
Benzothiopyranoindole-Based Antiproliferative Agents: Synthesis, Cytotoxicity, Nucleic Acids Interaction, and Topoisomerases Inhibition Properties. 201
5-Amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a Versatile Scaffold to Obtain Potent and Selective A3 Adenosine Receptor Antagonists 200
Medicinal chemistry of indolylglyoxylamide GABAA/BzR high affinity ligands: identification of novel anxiolytic/non sedative agents 200
Synthesis and functional evaluation of novel aldose reductase inhibitors bearing a spirobenzopyran scaffold 199
Benzo[d]isothiazoles and Matrix Metalloproteinases. Searching for Novel and Selective Inhibitors of MMP9 198
Synthesis of a Novel Purine-Containing Heterocyclic Ring System: 8,10-Dimethylindolo[2',3':5,6][1,2,4]triazino[4,3-f]purine-9,11(8H,10H,13H)dione 198
Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications 198
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 197
Pursuing Aldose Reductase Inhibitors through in Situ Cross-Docking and Similarity-Based Virtual Screening 196
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 196
Synthesis of novel 1-aryl[1]benzoxepino[5,4-c]pyrazole and [1]benzoxepino[5,4-d]pyrimidine derivatives 195
Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs 195
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 193
A New Approach to Control the Enigmatic Activity of Aldose Reductase 192
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 191
Synthesis of Purinobenzodiazepine and Purinobenzotriazocine derivatives, two new heterocyclic ring systems. 191
Novel, Highly Potent Aldose Reductase Inhibitors:Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic Acid Derivatives 189
Novel Potent and Selective Human Adenosine A3 Receptor Antagonists Containing the Pyrazolo[3,4-d]pyrimidine Ring System. Synthesis and Biological Evaluation 188
Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study 188
Preparation of benzofuran derivatives for use as AMPK activators 188
Novel N(2)-Substituted Pyrazolo[3,4-d]pyrimidine Adenosine A(3) Receptor Antagonists: Inhibition of A(3)-Mediated Human Glioblastoma Cell Proliferation (dagger) 186
FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells 185
Effects of the new aldose reductase inhibitor benzofuroxane derivative bf-5m on high glucose induced prolongation of cardiac qt interval and increase of coronary perfusion pressure 185
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model 184
Nuovi derivati acidi acetici quali potenti inibitori dell’Aldoso Reduttasi 182
Synthesis of novel pyrido[3',2':5,6]thiopyrano[3,2-b]indol-5(6H)-ones and 6H-pyrido[3',2':5,6]thiopyrano[4,3-b]quinolines,two new heterocyclic systems. 182
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 182
Novel treatments for anaplastic thyroid carcinoma 181
Pyrazolo[3,4,-d]pyrimidine-4-one Derivatives as Novel and Potent Inhibitors of Adenosine Deaminase 180
Novel quinazolinone-based 2,4-thiazolidinedione-3-acetic acid derivatives as potent aldose reductase inhibitors 180
Imidazo[1,2- a]pyridine derivatives as aldehyde dehydrogenase inhibitors: Novel chemotypes to target glioblastoma stem cells 178
Aldose reductase inhibitors: 2013-present 177
A 2,3-diphenylpyrido[1,2-a] pyrimidin-4-one derivative inhibits specific angiogenic factors induced by TNF-α 177
Synthesis and Biological Evaluation of Pyrido[1,2-d]pyrimidin-4-one Derivatives as Novel Aldose Reductase Inhibitors Exhibiting Antioxidant Activity 176
Microwave-assisted Suzuki Coupling in Aqueous Media: a Useful Tool for the Synthesis of 3-Arylindazole Derivatives 175
Geometrically Constrained Derivatives of Indolylglyoxylamides as Ligands Binding the GABAA/BzR Complex. 175
Small Molecules Containing the Benzo[d]isotiazole Ring System as Novel ATP-Competitive Inhibitors of Epidermal Growth Factor Receptor protein Tyrosine Kinase 172
Novel Aldose Reductase Acetic acid Inhibitors Bearing a Five Membered heterocyclic core 172
Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders 172
Derivati a nucleo benzo[d]isotiazol-3(2H)-one-1,1-diossido e loro impiego nel trattamento di tumori 172
Synthesis and biological activity of 1,4-dihydrobenzothiopyrano[4,3-c]pyrazole derivatives, novel pro-apoptotic mitochondrial targeted agents 171
A1 adenosine receptor antagonists, 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4-(10H)-ones (ATBIs) and N-alkyl and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs): different recognition of bovine and human binding sites 170
Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview 170
Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands 170
Naphtho[1,2-d]isothiazole Acetic Acid Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors 169
Spirohydantoin Derivatives of Thiopyrano[2,3-b]pyridin-4(4H)-one as Potent in Vitro and in Vivo Aldose Reductase Inhibitors 168
Tertiary amides with a five-membered heteroaromatic ring as new probes for the translocator protein 168
Derivati spiroidantoinici del Tiopirano[2,3-b]piridin-4(4H)-one quali potenti inibitori dell’aldoso reduttasi 167
The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors 167
Refinement of the translocator protein pharmacophore/receptor model via structure-activity relationships of novel N,N-dialkylindolylglyoxylamides 166
Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies 166
2-(phenylsulphonamido)-pyrazole derivatives as carbonic anhydrase inhibitors 165
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration 165
Totale 21.267
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.536
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.536
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.347 0 0 117 205 448 315 63 133 114 69 174 709
2022/20233.392 471 572 256 303 376 433 67 230 466 21 151 46
2023/20242.302 288 258 279 180 327 430 87 47 32 66 69 239
2024/20256.883 62 264 98 424 743 702 517 359 613 871 677 1.553
2025/20268.056 513 899 945 673 762 630 1.319 378 546 758 345 288
2026/20271.804 232 504 1.068 0 0 0 0 0 0 0 0 0
Totale 37.055